Tim peneliti ti Abramson Cancer Center (ACC) di University of Pennsylvania School of Medicine mendakan yén naha tumor panas atanapi tiis ditangtukeun ku inpormasi anu aya dina sél kanker sorangan. “Hot” tumors are often considered more sensitive to immunotherapy. In a new study published this week in Immunity, the researchers explored the role of “tumor heterogeneity”, namely the ability of tumor cells to move, replicate, metastasize and respond to treatment. These new findings can help oncologists more accurately tailor the unique tumor composition of patients.
Ben Stanger, profésor gastroenterologi sareng sél sareng biologi pangwangunan di University of Pennsylvania Perelman School of Medicine, nyarios yén derajat sél T katarik tumor diatur ku gén khusus spésifik. Supados tumuh tumuh, aranjeunna kedah nyingkahan serangan ku sistem imun. Aya dua cara: pikeun ngembangkeun janten tumor tiis, atanapi tumor panas anu tiasa nyéépkeun sél T, sacara efektif nangtayungan sél tumor tina ruksakna sistem imunitas pasién.
In this study, researchers found that whether a tumor is hot or cold determines whether it will respond to immunotherapy. Cold tumor cells produce a compound called CXCL1, which can instruct bone marrow cells to enter the tumor, keep T cells away from the tumor, and ultimately make the immunotherapy insensitive. In contrast, knocking out CXCL1 in cold tumors promotes T cell infiltration and sensitivity to immunotherapy.
Tim ngahasilkeun seri garis sél anu niru karakteristik tumor pankreas, kaasup jinis sél imun anu dikandungna. Di pikahareupeun, garis sél tumor ieu tiasa ngabantosan langkung ngaidentipikasi sareng ngaoptimalkeun pangobatan pikeun subtipe khusus pasién anu ngagaduhan sababaraha kaayaan heterogénitas tumor.
